Robert Knight
Chief Tech/Sci/R&D Officer at NEXIMMUNE, INC.
Profile
Robert Knight is currently the Chief Medical Officer at NexImmune, Inc. Prior to this, he was the Vice President-Clinical Development at Kite Pharma, Inc. from 2020 to 2021, the Vice President-Clinical Research at Sorrento Therapeutics, Inc. from 2017 to 2020, and the Corporate Vice President at Celgene Corp.
from 2001 to 2017.
Dr. Knight received his undergraduate degree from the US Military Academy and his doctorate degree from The State University of New York.
Robert Knight active positions
| Companies | Position | Start |
|---|---|---|
| NEXIMMUNE, INC. | Chief Tech/Sci/R&D Officer | 2020-12-31 |
Former positions of Robert Knight
| Companies | Position | End |
|---|---|---|
| KITE PHARMA INC | Corporate Officer/Principal | 2020-12-31 |
| SORRENTO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-04-30 |
| CELGENE | Corporate Officer/Principal | 2017-05-31 |
Training of Robert Knight
| US Military Academy | Undergraduate Degree |
| The State University of New York | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| NEXIMMUNE, INC. | Health Technology |
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Kite Pharma, Inc.
 Kite Pharma, Inc. BiotechnologyHealth Technology Kite Pharma, Inc. engages in the the development and commercialization of cancer immunotherapy products. Its products include chimeric antigen receptor (CAR) and T cell receptor (TCR), which address both hematological and solid cancers. The company was founded by Arie S. Belldegrun, James S. Economou, and Joshua A. Kazam on 2009 and is headquartered in Santa Monica, CA. | Health Technology |
- Stock Market
- Insiders
- Robert Knight
